Relative risk for achieving normal SF-36 PCS and MCS scores among patients who achieved ASDAS inactive disease at weeks 52 and 104a.
| Patients with ASDAS Inactive Disease | ||
|---|---|---|
| No | Yes | |
| SF-36 PCS Score | ||
| PCS ≥ 50 at Week 52, n (%) | 20 (9.8) | 60 (57.4) |
| Relative risk (p value) | 5.5 (< 0.0001) | |
| PCS ≥ 50 at Week 104, n (%) | 17 (10.5) | 76 (65.5) |
| Relative risk (p value) | 6.1 (< 0.0001) | |
| SF-36 MCS Score | ||
| MCS ≥ 50 at Week 52, n (%) | 101 (49.5) | 68 (64.8) |
| Relative risk (p value) | 1.1 (0.0833) | |
| MCS ≥ 50 at week 104, n (%) | 81 (50.0) | 86 (74.1) |
| Relative risk (p value) | 1.1 (0.0454) | |
↵a All patients who were randomized to placebo switched to golimumab at Week 16 (early escape) or Week 24 (prespecified crossover). ASDAS: Ankylosing Spondylitis Disease Activity Score; SF-36 PCS/MCS: Medical Outcomes Study Short Form-36 physical component summary/mental component summary.